Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/13/2017 02/14/2017 02/15/2017 02/16/2017 02/17/2017 Date
14.5(c) 14.6(c) 14.5(c) 14.5(c) 15(c) Last
494 422 473 747 792 734 959 986 1 159 623 Volume
+1.40% +0.69% -0.68% 0.00% +3.45% Change
More quotes
Financials ($)
Sales 2017 168 M
EBIT 2017 -20,2 M
Net income 2017 -21,3 M
Debt 2017 -
Yield 2017 -
Sales 2018 204 M
EBIT 2018 7,68 M
Net income 2018 1,58 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 500,00
Capi. / Sales2017 3,92x
Capi. / Sales2018 3,23x
Capitalization 659 M
More Financials
Company
Vanda Pharmaceuticals, Inc. engages in the research, development, and commercialization of biopharmaceutical products.It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder.Its product portfolio includes HETLIOZ,... 
More about the company
Surperformance© ratings of Vanda Pharmaceuticals Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on VANDA PHARMACEUTICALS INC.
02/17 VANDA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
02/15 VANDA PHARMACEUTICALS : reports 4Q loss
02/15 VANDA PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Fina..
02/15 VANDA PHARMACEUTICALS : Reports Fourth Quarter 2016 and Full Year 2016 Financial..
02/08 VANDA PHARMACEUTICALS : VNDA) Gains with Q4 Results Due
02/02 VANDA PHARMACEUTICALS : Patent Issued for Treatment of Circadian Rhythm Disorder..
01/30 VANDA PHARMACEUTICALS : Expected to Post q2 2017 Earnings of ($0.04) Per Share (..
01/26 VANDA PHARMACEUTICALS : to Announce Fourth Quarter and Full Year 2016 Financial ..
01/19 VANDA PHARMACEUTICALS : Reports Preliminary Fourth Quarter and Full Year 2016 Re..
01/19 VANDA PHARMACEUTICALS : to Announce Fourth Quarter and Full Year 2016 Financial ..
More news
Sector news : Bio Therapeutic Drugs
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
02/13 TEVA PHARMACEUTICAL INDUSTRIES : seeks CEO with pharma background to lead recove..
02/09DJAppeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol Drug
02/08 Weak pound buoys GSK but drugmaker warns on 2017 generic threat
More sector news : Bio Therapeutic Drugs
Latest Tweets
02/18Vanda Pharmaceuticals Inc. $VNDA Lifted to “Hold” at Zacks Investment Researc.. 
02/18Vanda Pharmaceuticals upgraded by Zacks Investment Research to hold.  
02/15Vanda Pharmaceuticals : Reports Fourth Quarter 2016 and Full Year 2016 Financ.. 
02/15Top Earnings Wed 2/15 Aft: $MMLP $MOH $MRO $NGD $NLY $NTAP $NTES $OIS $PKD $S.. 
02/11Highbridge Capital Management LLC Takes Position in Vanda Pharmaceuticals Inc.. 
More tweets
Qtime:18
News from SeekingAlpha
02/15 Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q4 2016 Results - ..
02/15 Vanda Pharmaceuticals beats by $0.08, misses on revenue
02/14 Notable earnings after Wednesday?s close
01/09 Vanda Pharmaceuticals reports preliminary Q4 and FY2016 results and 2017 guid..
2016 VANDA : Valued Like A Plain Pharma Company, But Isn't One
Advertisement
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Full-screen chart
Technical analysis trends VANDA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 22,3 $
Spread / Average Target 48%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Senior VP
Paolo Baroldi Chief Medical Officer & Senior Vice President
Vincent J. Milano Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS ..-5.96%659
AMGEN, INC.18.52%127 620
CELGENE CORPORATION4.67%94 258
GILEAD SCIENCES, INC.-2.46%92 024
REGENERON PHARMACEUTIC..1.11%39 375
ACTELION LTD21.09%28 677
More Results